TSX: ATE   CAD ${{ stocks['ATE.TO'].LastPrice }}
Last updated: {{ getStockDate(stocks['ATE.TO']) }} ET
OTCQX: ATBPF   USD ${{ stocks['ATBPF'].LastPrice }}
Last updated: {{ getStockDate(stocks['ATBPF']) }} ET
CAD ${{ getMCap(stocks['ATE.TO']) }}M
MARKET CAP
CAD ${{ stocks['ATE.TO'].YearHigh }}/${{ stocks['ATE.TO'].YearLow }}
52-WEEK HIGH/LOW
{{ stocks['ATE.TO'].AverageDailyVolume3Month }}
AVG. DAILY TRADING VOLUME
11%
INSIDER OWNERSHIP

Corporate Presentation

Learn how Antibe is aiming to change the game in pain and inflammation medicine. Delve into our market opportunity, drug pipeline and the science that underlies our drug platform.

Last updated: April 2021

ANALYST COVERAGE

FIRM                                                                                         ANALYST

Canaccord Genuity Capital Markets                           Tania Gonsalves, CFA
Echelon Wealth Partners                                                 Stefan Quenneville, CFA
Leede Jones Gable                                                             Douglas Loe, PhD MBA
Maxim Group                                                                        Jason McCarthy, PhD
Paradigm Capital                                                                Scott McAuley, PhD

The opinions, forecasts and estimates of these analysts do not represent those of Antibe Therapeutics or its directors.

 

Attention

This is an external link. Click “OK” to continue.

CANCEL OK